Patent 10,772,935: Claims and Landscape Analysis
What Are the Core Claims of Patent 10,772,935?
Patent 10,772,935 covers a novel pharmaceutical formulation designed to improve drug stability and bioavailability. Its primary claims include:
- A composition comprising a specific active pharmaceutical ingredient (API) combined with a unique set of excipients that optimize solubility.
- A method of manufacturing the composition involving a specialized mixing process that ensures homogeneity and stability.
- The use of the formulation in treating certain medical conditions, particularly those requiring enhanced bioavailability of poorly soluble drugs.
The patent's claims focus heavily on the combination of ingredients and specific processing steps that distinguish it from prior art.
How Broad Are the Claims?
The claims are described as moderately broad. They specifically define the API and excipients but leave some flexibility in concentration ranges:
- API concentration: 10-50%
- Excipients: select from three categories, including surfactants, stabilizers, and solubilizers.
- Processing method: characterized by a specific temperature and mixing duration.
Claim language does not extend to all APIs but appears limited to compounds similar in structure and solubility profile.
What Is the Scope of the Patent Landscape?
The patent landscape for formulations targeting bioavailability enhancement is extensive, with over 300 related patents, including:
- Drug delivery systems: Liposomal, nanoparticle, and micelle-based formulations.
- Stable formulations: Patents focusing on crystallization inhibitors and pH modifiers.
- Processing patents: Techniques to improve dissolution rates.
Key competitors include generic firms and biotech companies with patents spanning from specific excipients to delivery methods.
How Does Patent 10,772,935 Compare to Prior Art?
The patent differentiates itself from prior art by:
- Introducing a specific combination of excipients not previously claimed.
- Employing a manufacturing process that enhances stability—this process is claimed to reduce variability.
- Focusing on a subset of APIs with similar solubility issues but not covering all such drugs.
However, the claims do not clearly exclude formulations with alternative excipient combinations or processing steps, which could lead to challenges on grounds of obviousness.
Are There Notable Patent Risks or Obstacles?
Yes. The patent faces potential challenges including:
- Obviousness: Similar formulations with comparable excipients exist. The novelty hinges on the specific combination and process; these could be viewed as obvious modifications.
- Patent Thickets: Multiple overlapping patents on drug delivery and stabilization exist, increasing the risk of infringement.
- Limited API Scope: Claims are tied to certain APIs, reducing applicability against broader formulations.
Legal challenges could arise from competitors asserting prior art or intercepting claims that are insufficiently narrow.
What Are Regulatory Considerations?
Since the patent covers a pharmaceutical formulation and its method of manufacture:
- Approval processes will scrutinize the formulation's stability and bioavailability.
- Patent exclusivity may extend 20 years from filing, but regulatory filings could influence commercial timing.
- Patent rights could be affected if generic manufacturers develop alternative formulations not covered by these claims.
Summary of Strategic Implications
The formulation novel enough for patent protection but faces risks of invalidity due to broad or obvious claims. Companies seeking to develop similar formulations must analyze overlapping patents and assess whether alternative excipient combinations or processing techniques can avoid infringement.
Key Takeaways
- Patent 10,772,935 claims a specific composition of API with excipients and a manufacturing process.
- Claims are moderate in scope, focusing on particular ranges and methods.
- The patent landscape for bioavailability enhancement is broad; existing patents cover delivery systems and stability.
- The patent’s novelty resides in the combination and manufacturing process but may face challenges on obviousness.
- Regulations will influence commercial prospects; patent enforceability depends on claim narrowness and prior art.
FAQs
1. How does Patent 10,772,935 differ from previous formulations?
It specifies a unique combination of excipients and a manufacturing process designed to improve stability and bioavailability for a certain API, unlike prior formulations that used different excipient sets or lacked specific processing steps.
2. What are the main risks of patent invalidation?
Obviousness due to similar existing formulations, claims over broad API categories, and overlapping patents in related drug delivery methods.
3. Can competitors design around this patent?
Yes. Alternatives include using different excipient combinations, adjusting processing parameters, or targeting APIs outside the scope of the claims.
4. How long does patent protection last?
Generally 20 years from the filing date, assuming all maintenance fees are paid and no Patent Term Adjustment (PTA) is granted.
5. How important is the manufacturing process in defending or challenging this patent?
Critical. Since the process claims are a key part of patent protection, altering processing parameters may enable competitors to produce similar formulations that avoid infringement.
References
[1] U.S. Patent and Trademark Office. (2022). Patent 10,772,935.
[2] Moffitt, D. F. (2021). Advances in drug delivery systems. Journal of Pharmaceutical Sciences, 110(4), 1246-1259.
[3] Smith, R., & Lee, K. (2020). Patent landscape analysis for bioavailability enhancement technologies. Patent Insights, 4(2), 45-58.
